Previous 10 | Next 10 |
Gainers: Orbsat (OSAT) +86%.BSQUARE (BSQR) +71%.PFSweb (PFSW) +36%.Advaxis (ADXS) +35%.Powerbridge Technologies (PBTS) +34%.Bridgeline Digital (BLIN) +31%.Sequential Brands Group (SQBG) +24%.GasLog Partners (GLOP) +24%.BioHiTech Global (BHTG) +20%.Data Storage (DTST) +19%.Losers: Pop Culture ...
Ashford Hospitality (AHT) -29% after announces reverse stock split and announces preliminary RevPAR results for Q2 2021Provention Bio (PRVB) -22% after receiving CRL for teplizumab applicationDiDi Global (DIDI) -20% DiDi Global says app takedown in China may hurt...
Provention Bio (PRVB) plummets 21.6% premarket in reaction to the announcement that the FDA has issued a Complete Response Letter ((CRL)) for its Biologics License Application ((BLA)) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.In the CRL,...
Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstandi...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Gainers: Alector (ALEC) +69%. Lucira Health (LHDX) +9%. Provention Bio (PRVB) +7%.Losers: Iterum Therapeutics (ITRM) -34%. Arrowhead Pharmaceuticals (ARWR) -26%. Alterity Therapeutics (ATHE) -21%. Citius Pharmaceuticals (CTXR) -20%. TRxADE HEALTH (MEDS) -17%. For fu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a big quarter for biotech stocks. Biogen (NASDAQ: BIIB ) had a major breakthrough with the approval of its Alzheimer’s vaccine aducanumab, which is sold under the brand name Aduhelm. It mar...
The Advisory Committee voted 10-7 favoring an approval recommendation for teplizumab. The FDA has given conflicting signals about approval. PDUFA is on July 2. For further details see: Provention Bio: PDUFA Ahead, But Uncertainties Abound
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The stock market got the jobs report it apparently was waiting for, as May's payrolls growth came in short of expectations and led investors ...
Shares of Provention Bio (NASDAQ: PRVB) crashed 28.8% as of the market close on Friday. The huge decline came after a U.S. Food and Drug Administration (FDA) advisory committee voted 10-7 in favor of recommending approval of teplizumab in delaying type 1 diabetes. Investors were...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...